HCM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 19.38 USD with a low forecast of 13.75 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

1 Sell

Hold

Current: 0.000

Low

13.75

Averages

19.38

High

25.00

Current: 0.000

Low

13.75

Averages

19.38

High

25.00

BofA

Buy

downgrade

$25 -> $22

2026-01-06

New

Reason

BofA

Price Target

$25 -> $22

2026-01-06

New

downgrade

Buy

Reason

BofA lowered the firm's price target on Hutchmed to $22 from $25 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Morgan Stanley

Equal Weight -> Underweight

downgrade

$18

2025-09-22

Reason

Morgan Stanley

Price Target

$18

2025-09-22

downgrade

Equal Weight -> Underweight

Reason

Morgan Stanley downgraded Hutchmed to Underweight from Equal Weight with a price target of $13.75, down from $18. The company reduced its commercial guidance amid a restructuring and its \"lackluster\" near-term growth could drive a valuation de-rating, the analyst tells investors in a research note. The firm says Hutchmed's approved assets could be entering a period of declining product life cycles and patent expirations.

BofA

Buy

upgrade

$27 -> $28

2025-07-22

Reason

BofA

Price Target

$27 -> $28

2025-07-22

upgrade

Buy

Reason

BofA raised the firm's price target on Hutchmed to $28 from $27 and keeps a Buy rating on the shares. The firm updated its model to include a revenue build for tazemetostat and adjust expectations slightly for operating expenses, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.

HSBC

Buy

Hold

downgrade

$14.70

2025-05-13

Reason

HSBC

Price Target

$14.70

2025-05-13

downgrade

Buy

Hold

Reason

HSBC downgraded Hutchmed to Hold from Buy with a $14.70 price target.

Valuation Metrics

The current forward P/E ratio for HUTCHMED (China) Ltd (HCM.O) is 14.28, compared to its 5-year average forward P/E of 19.36. For a more detailed relative valuation and DCF analysis to assess HUTCHMED (China) Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

19.36

Current PE

14.28

Overvalued PE

341.88

Undervalued PE

-303.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-80.02

Current EV/EBITDA

-458.20

Overvalued EV/EBITDA

79.39

Undervalued EV/EBITDA

-239.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.52

Current PS

3.61

Overvalued PS

9.43

Undervalued PS

1.61

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HCM News & Events

Events Timeline

No data

News

9.0

01-09NASDAQ.COM

ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis

9.0

01-07Benzinga

HUTCHMED Reports Phase 3 Data for Sovleplenib, Plans NDA Submission in 2026

9.0

01-07NASDAQ.COM

HUTCHMED's ESLIM-02 Trial Meets Primary Endpoint; NDA Submission Planned for 2026

People Also Watch

Frequently Asked Questions

What is HUTCHMED (China) Ltd (HCM) stock price today?

The current price of HCM is 14.72 USD — it has decreased -0.34 % in the last trading day.

What is HUTCHMED (China) Ltd (HCM)'s business?

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

What is the price predicton of HCM Stock?

What is HUTCHMED (China) Ltd (HCM)'s revenue for the last quarter?

HUTCHMED (China) Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is HUTCHMED (China) Ltd (HCM)'s earnings per share (EPS) for the last quarter?

HUTCHMED (China) Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for HUTCHMED (China) Ltd (HCM)'s fundamentals?

The market is revising No Change the revenue expectations for HCM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -8.11%.

How many employees does HUTCHMED (China) Ltd (HCM). have?

HUTCHMED (China) Ltd (HCM) has 1811 emplpoyees as of January 10 2026.

What is HUTCHMED (China) Ltd (HCM) market cap?

Today HCM has the market capitalization of 2.57B USD.